A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way?

Journal of Biomolecular Screening

Volumn 20, Issue 8, 2015, Pages 1040-1051

  Taylor, Jessica ^a   Woodcock, Simon ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CRISPR Cas; functional genomics; precise genome editing; RNAi; screening

Indexed keywords

CRISPR CAS SYSTEM; FUNCTIONAL GENOMICS; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENETICS; GENOMICS; PROCEDURES; RNA EDITING;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; RNA EDITING; RNA INTERFERENCE;

EID: 84939784406     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115590069     Document Type: Review

References (106)

1. Bharucha N., Kumar A., Yeast Genomics and Drug Target Identification. Comb. Chem. High Through. Screen. 2007, 10 (8), 618-634.
2. Sugimoto A., High-Throughput RNAi in Caenorhabditis elegans: Genome-Wide Screens and Functional Genomics. Differentiation. 2004, 72 (2-3), 81-91.
3. Mohr S. E., Hu Y., Kim K.,. Resources for Functional Genomics Studies in Drosophila melanogaster. Genetics. 2014, 197 (1), 1-18.
4. Chen K. F., Crowther D. C., Functional Genomics in Drosophila Models of Human Disease. Brief. Funct. Genom. 2012, 11 (5), 405-415.
5. Chatterjee S., Lufkin T., Fishing for Function: Zebrafish BAC Transgenics for Functional Genomics. Molec. bioSystems. 2011, 7 (8), 2345-2351.
6. Hicks G. G., Shi E. G., Li X. M.,. Functional Genomics in Mice by Tagged Sequence Mutagenesis. Nature Genet. 1997, 16 (4), 338-344.
7. Kramer R., Cohen D., Functional Genomics to New Drug Targets. Nature Rev. Drug Disc. 2004, 3 (11), 965-972.
8. Heynen-Genel S., Pache L., Chanda S. K.,. Functional Genomic and High-Content Screening for Target Discovery and Deconvolution. Expert Opin. Drug Disc. 2012, 7 (10), 955-968.
9. Moody S. E., Boehm J. S., Barbie D. A.,. Functional Genomics and Cancer Drug Target Discovery. Curr. Opin. Molec. Ther. 2010, 12 (3), 284-293.
10. Stanford W. L., Cohn J. B., Cordes S. P., Gene-Trap Mutagenesis: Past, Present and Beyond. Nat. Rev. Genet. 2001, 2 (10), 756-768.
11. Müller U., Ten Years of Gene Targeting: Targeted Mouse Mutants, from Vector Design to Phenotype Analysis. Mech. Dev. 1999, 82 (1-2), 3-21.
12. Streit S., Michalski C. W., Erkan M.,. Northern Blot Analysis for Detection and Quantification of RNA in Pancreatic Cancer Cells and Tissues. Nat. Protoc. 2009, 4 (1), 37-43.
13. Kassner P. D., Discovery of Novel Targets with High Throughput RNA Interference Screening. Comb. Chem. High Through. Screen. 2008, 11 (3), 175-184.
14. Mohr S. E., Smith J. A., Shamu C. E.,. RNAi Screening Comes of Age: Improved Techniques and Complementary Approaches. Nature Rev. Molec. Cell Biol. 2014, 15 (9), 591-600.
15. Fire A., Xu S., Montgomery M. K.,. Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis elegans. Nature. 1998, 391 (6669), 806-811.
16. Dykxhoorn D. M., Lieberman J., The Silent Revolution: RNA Interference as Basic Biology, Research Tool, and Therapeutic. Annu. Rev. Med. 2005, 56, 401-423.
17. Merkling S. H., van Rij R. P., Beyond RNAi: Antiviral Defense Strategies in Drosophila and Mosquito. J. Insect Physiol. 2013, 59 (2), 159-170.
18. Rao D. D., Vorhies J. S., Senzer N.,. siRNA vs. shRNA: Similarities and Differences. Adv. Drug Deliv. Rev. 2009, 61 (9), 746-759.
19. Tschöp K., Conery A. R., Litovchick L.,. A Kinase shRNA Screen Links LATS2 and the pRB Tumor Suppressor. Genes Dev. 2011, 25 (8), 814-830.
20. Nagaoka-Yasuda R., Matsuo N., Perkins B.,. An RNAi-Based Genetic Screen for Oxidative Stress Resistance Reveals Retinol Saturase as a Mediator of Stress Resistance. Free Radic. Biol. Med. 2007, 43 (5), 781-788.
21. Huang X., Wang J. Y. J., Lu X., Systems Analysis of Quantitative shRNA-Library Screens Identifies Regulators of Cell Adhesion. BMC Syst. Biol. 2008, 2, 49.
22. Luo J., Emanuele M. J., Li D.,. A Genome-Wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene. Cell. 2009, 137 (5), 835-848.
23. Mullenders J., Fabius A. W. M., Madiredjo M.,. A Large Scale shRNA Barcode Screen Identifies the Circadian Clock Component ARNTL as Putative Regulator of the p53 Tumor Suppressor Pathway. PLoS One. 2009, 4 (3), e4798.
24. Yeung M. L., Houzet L., Yedavalli V. S. R. K.,. A Genome-Wide Short Hairpin RNA Screening of Jurkat T-Cells for Human Proteins Contributing to Productive HIV-1 Replication. J. Biol. Chem. 2009, 284 (29), 19463-19473.
25. Kimura J., Nguyen S. T., Liu H.,. A Functional Genome-Wide RNAi Screen Identifies TAF1 as a Regulator for Apoptosis in Response to Genotoxic Stress. Nucleic Acids Res. 2008, 36 (16), 5250-5259.
26. Smith J. A., White E. A., Sowa M. E.,. Genome-Wide siRNA Screen Identifies SMCX, EP400, and Brd4 as E2-Dependent Regulators of Human Papillomavirus Oncogene Expression. Proc. Natl. Acad. Sci. USA. 2010, 107 (8), 3752-3757.
27. Karlas A., Machuy N., Shin Y.,. Genome-Wide RNAi Screen Identifies Human Host Factors Crucial for Influenza Virus Replication. Nature. 2010, 463 (7282), 818-822.
28. Mukherji M., Bell R., Supekova L.,. Genome-Wide Functional Analysis of Human Cell-Cycle Regulators. Proc. Natl. Acad. Sci. USA. 2006, 103 (40), 14819-14824.
29. Sims D., Mendes-Pereira A. M., Frankum J.,. High-Throughput RNA Interference Screening Using Pooled shRNA Libraries and Next Generation Sequencing. Genome Biol. 2011, 12 (10), R104.
30. Kenrick M., Hancock S., Stubbs S.,. siRNA Screening of the Cell Cycle with Two Dynamic GFP Sensors. Discovery. 2005, 1, 1-19.
31. Qiu S., Adema C. M., Lane T., A Computational Study of Off-Target Effects of RNA Interference. Nucleic Acids Res. 2005, 33 (6), 1834-1847.
32. Bhinder B., Djaballah H., Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens. Comb. Chem. High Throughput Screen. 2013, 16 (9), 665-681.
33. Ishino Y., Shinagawa H., Makino K.,. Nucleotide Sequence of the IAP Gene, Responsible for Alkaline Phosphatase Isozyme Conversion in Escherichia coli, and Identification of the Gene Product. J. Bacteriol. 1987, 169 (12), 5429-5433.
34. Cong L., Ran F. A., Cox D.,. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science. 2013, 339 (6121), 819-823.
35. Mali P., Yang L., Esvelt K. M.,. RNA-Guided Human Genome Engineering via Cas9. Science. 2013, 339 (6121), 823-826.
36. Ding Q., Regan S. N., Xia Y.,. Enhanced Efficiency of Human Pluripotent Stem Cell Genome Editing through Replacing TALENs with CRISPRs. Cell Stem Cell. 2013, 12 (4), 393-394.
37. Makarova K. S., Haft D. H., Barrangou R.,. Evolution and Classification of the CRISPR-Cas Systems. Nat. Rev. Microbiol. 2011, 9 (6), 467-477.
38. Sorek R., Lawrence C. M., Wiedenheft B., CRISPR-Mediated Adaptive Immune Systems in Bacteria and Archaea. Annu. Rev. Biochem. 2013, 82, 237-266.
39. Ran F. A., Hsu P. D., Wright J.,. Genome Engineering Using the CRISPR-Cas9 System. Nat. Protoc. 2013, 8 (11), 2281-2308.
40. Carlson D. F., Fahrenkrug S. C., Hackett P. B., Targeting DNA with Fingers and TALENs. Mol. Ther. Nucleic Acids. 2012, 1, e3.
41. Keith Joung J., Sander J. D., TALENs: A Widely Applicable Technology for Targeted Genome Editing. Nat. Rev. Mol. Cell Biol. 2012, 14 (1), 49-55.
42. Chandrasekharan S., Kumar S., Valley C. M.,. Proprietary Science, Open Science and the Role of Patent Disclosure: The Case of Zinc-Finger Proteins. Nat. Biotechnol. 2009, 27 (2), 140-144.
43. Kim E., Kim S., Kim D. H.,. Precision Genome Engineering with Programmable DNA-Nicking Enzymes. Genome Res. 2012, 22 (7), 1327-1333.
44. Lee H. J., Kweon J., Kim E.,. Targeted Chromosomal Duplications and Inversions in the Human Genome Using Zinc Finger Nucleases. Genome Res. 2012, 22 (3), 539-548.
45. Xue W., Chen S., Yin H.,. CRISPR-Mediated Direct Mutation of Cancer Genes in the Mouse Liver. Nature. 2014, 514 (7522), 380-384.
46. Long C., McAnally J. R., Shelton J. M.,. Prevention of Muscular Dystrophy in Mice by CRISPR/Cas9-Mediated Editing of Germline DNA. Science. 2014, 345 (6201), 1184-1188.
47. Heckl D., Kowalczyk M. S., Yudovich D.,. Generation of Mouse Models of Myeloid Malignancy with Combinatorial Genetic Lesions Using CRISPR-Cas9 Genome Editing. Nat. Biotechnol. 2014, 32 (9), 941-946.
48. Wang T., Wei J. J., Sabatini D. M.,. Genetic Screens in Human Cells Using the CRISPR-Cas9 System. Science. 2014, 343 (6166), 80-84.
49. Zhou Y., Zhu S., Cai C.,. High-Throughput Screening of a CRISPR/Cas9 Library for Functional Genomics in Human Cells. Nature. 2014, 509 (7501), 487-491.
50. Koike-Yusa H., Li Y., Tan E. P.,. Genome-Wide Recessive Genetic Screening in Mammalian Cells with a Lentiviral CRISPR-Guide RNA Library. Nat. Biotechnol. 2014, 32 (3), 267-273.
51. Shalem O., Sanjana N. E., Hartenian E.,. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science. 2014, 343 (6166), 84-87.
52. Ran F. A., Hsu P. D., Lin C.-Y.,. Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity. Cell. 2013, 154 (6), 1380-1389.
53. Caldecott K. W., Single-Strand Break Repair and Genetic Disease. Nature Rev. Genet. 2008, 9 (8), 619-631.
54. Caldecott K. W., DNA Single-Strand Break Repair. Exper. Cell Res. 2014, 329 (1), 2-8.
55. Dianov G. L., Hubscher U., Mammalian Base Excision Repair: The Forgotten Archangel. Nucleic Acids Res. 2013, 41 (6), 3483-3490.
56. Heintze J., Luft C., Ketteler R., A CRISPR CASe for High-Throughput Silencing. Front. Genet. 2013, 4, 193.
57. Qi L. S., Larson M. H., Gilbert L. A.,. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. Cell. 2013, 152 (5), 1173-1183.
58. Larson M. H., Gilbert L. A., Wang X.,. CRISPR Interference (CRISPRi) for Sequence-Specific Control of Gene Expression. Nat. Protoc. 2013, 8 (11), 2180-2196.
59. Cheng A. W., Wang H., Yang H.,. Multiplexed Activation of Endogenous Genes by CRISPR-on, an RNA-Guided Transcriptional Activator System. Cell Res. 2013, 23 (10), 1163-1171.
60. Gilbert L. A., Larson M. H., Morsut L.,. CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes. Cell. 2013, 154 (2), 442-451.
61. Gilbert L. A., Horlbeck M. A., Adamson B.,. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014, 159 (3), 647-661.
62. Tanenbaum M. E., Gilbert L. A., Qi L. S.,. A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging. Cell. 2014, 159 (3), 635-646.
63. Malina A., Mills J. R., Cencic R.,. Repurposing CRISPR/Cas9 for In Situ Functional Assays. Genes Dev. 2013, 27 (23), 2602-2614.
64. Platt R. J., Chen S., Zhou Y.,. CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling. Cell. 2014, 159 (2), 440-455.
65. Woodcock S. A., Rushton H. J., Castaneda-Saucedo E.,. Tiam1-Rac Signaling Counteracts Eg5 during Bipolar Spindle Assembly to Facilitate Chromosome Congression. Curr. Biol. 2010, 20 (7), 669-675.
66. Cullen B. R., Enhancing and Confirming the Specificity of RNAi Experiments. Nature Meth. 2006, 3 (9), 677-681.
67. Shah S. A., Erdmann S., Mojica F. J. M.,. Protospacer Recognition Motifs: Mixed Identities and Functional Diversity. RNA Biol. 2013, 10 (5), 891-899.
68. Hsu P. D., Scott D. A., Weinstein J. A.,. DNA Targeting Specificity of RNA-Guided Cas9 Nucleases. Nat. Biotechnol. 2013, 31 (9), 827-832.
69. Ranganathan V., Wahlin K., Maruotti J.,. Expansion of the CRISPR-Cas9 Genome Targeting Space through the Use of H1 Promoter-Expressed Guide RNAs. Nat. Commun. 2014, 5, 4516.
70. Fonfara I., Le Rhun A., Chylinski K.,. Phylogeny of Cas9 Determines Functional Exchangeability of Dual-RNA and Cas9 among Orthologous Type II CRISPR-Cas systems. Nucleic Acids Res. 2014, 42 (4), 2577-2590.
71. Hou Z., Zhang Y., Propson N. E.,. Efficient Genome Engineering in Human Pluripotent Stem Cells Using Cas9 from Neisseria meningitidis. Proc. Natl. Acad. Sci. USA. 2013, 110 (39), 15644-15649.
72. Zhang Y., Ge X., Yang F.,. Comparison of Non-Canonical PAMs for CRISPR/Cas9-Mediated DNA Cleavage in Human Cells. Sci. Rep. 2014, 4, 5405.
73. Jackson A. L., Burchard J., Leake D.,. Position-Specific Chemical Modification of siRNAs Reduces ;Off-Target; Transcript Silencing. RNA. 2006, 12 (7), 1197-1205.
74. Jackson A. L., Burchard J., Schelter J.,. Widespread siRNA 'Off-Target' Transcript Silencing Mediated by Seed Region Sequence Complementarity. RNA. 2006, 12 (7), 1179-1187.
75. Yilmazel B., Hu Y., Sigoillot F.,. Online GESS: Prediction of miRNA-Like Off-Target Effects in Large-Scale RNAi Screen Data by Seed Region Analysis. BMC Bioinformatics. 2014, 15, 192.
76. Buehler E., Khan A. A., Marine S.,. siRNA Off-Target Effects in Genome-Wide Screens Identify Signaling Pathway Members. Sci. Rep. 2012, 2, 428.
77. Jackson A. L., Linsley P. S., Recognizing and Avoiding siRNA Off-Target Effects for Target Identification and Therapeutic Application. Nat. Rev. Drug Discov. 2010, 9 (1), 57-67.
78. Shen B., Zhang W., Zhang J.,. Efficient Genome Modification by CRISPR-Cas9 Nickase with Minimal Off-Target Effects. Nat. Methods. 2014, 11 (4), 399-402.
79. Veres A., Gosis B. S., Ding Q.,. Low Incidence of Off-Target Mutations in Individual CRISPR-Cas9 and TALEN Targeted Human Stem Cell Clones Detected by Whole-Genome Sequencing. Cell Stem Cell. 2014, 15 (1), 27-30.
80. Pattanayak V., Lin S., Guilinger J. P.,. High-Throughput Profiling of Off-Target DNA Cleavage Reveals RNA-Programmed Cas9 Nuclease Specificity. Nat. Biotechnol. 2013, 31 (9), 839-843.
81. Cradick T. J., Fine E. J., Antico C. J.,. CRISPR/Cas9 Systems Targeting '-Globin and CCR5 Genes Have Substantial Off-Target Activity. Nucleic Acids Res. 2013, 41 (20), 9584-9592.
82. Fu Y., Foden J. A., Khayter C.,. High-Frequency Off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells. Nat. Biotechnol. 2013, 31 (9), 822-826.
83. Sternberg S. H., Redding S., Jinek M.,. DNA Interrogation by the CRISPR RNA-Guided Endonuclease Cas9. Nature. 2014, 507 (7490), 62-67.
84. Wu X., Scott D. A., Kriz A. J.,. Genome-Wide Binding of the CRISPR Endonuclease Cas9 in Mammalian Cells. Nat. Biotechnol. 2014, 32 (7), 670-676.
85. Kuscu C., Arslan S., Singh R.,. Genome-Wide Analysis Reveals Characteristics of Off-Target Sites Bound by the Cas9 Endonuclease. Nat. Biotechnol. 2014, 32 (7), 677-683.
86. Jiang W., Bikard D., Cox D.,. RNA-Guided Editing of Bacterial Genomes Using CRISPR-Cas Systems. Nat. Biotechnol. 2013, 31 (3), 233-239.
87. Naito Y., Ui-Tei K., Designing Functional siRNA with Reduced Off-Target Effects. siRNA Design. 2012, 942, 57-68.
88. Liu Q., Xu Q., Zheng V. W.,. Multi-Task Learning for Cross-Platform siRNA Efficacy Prediction: An In-Silico Study. BMC Bioinformatics. 2010, 11, 181.
89. Fu Y., Sander J. D., Reyon D.,. Improving CRISPR-Cas Nuclease Specificity Using Truncated Guide RNAs. Nat. Biotechnol. 2014, 32 (3), 279-284.
90. Zhao Y., Dai Z., Liang Y.,. Sequence-Specific Inhibition of microRNA via CRISPR/CRISPRi System. Sci. Rep. 2014, 4, 3943.
91. Landry J. J. M., Pyl P. T., Rausch T.,. The Genomic and Transcriptomic Landscape of a HeLa Cell Line. Genes Genom. Genet. 2013, 3 (8), 1213-1224.
92. Carralot J.-P., Kim T.-K., Lenseigne B.,. Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure. J. Biomol. Screen. 2009, 14 (2), 151-160.
93. Canatella P. J., Karr J. F., Petros J. A.,. Quantitative Study of Electroporation-Mediated Molecular Uptake and Cell Viability. Biophys. J. 2001, 80 (2), 755-764.
94. Lenz P., Bacot S. M., Frazier-Jessen M. R.,. Nucleoporation of Dendritic Cells: Efficient Gene Transfer by Electroporation into Human Monocyte-Derived Dendritic Cells. FEBS Lett. 2003, 538 (1-3), 149-154.
95. Uchida E., Mizuguchi H., Ishii-Watabe A.,. Comparison of the Efficiency and Safety of Non-Viral Vector-Mediated Gene Transfer into a Wide Range of Human Cells. Biol. Pharm. Bull. 2002, 25 (7), 891-897.
96. Ramakrishna S., Kwaku Dad A.-B., Beloor J.,. Gene Disruption by Cell-Penetrating Peptide-Mediated Delivery of Cas9 Protein and Guide RNA. Genome Res. 2014, 24 (6), 1020-1027.
97. Endoh T., Ohtsuki T., Cellular siRNA Delivery Using Cell-Penetrating Peptides Modified for Endosomal Escape. Adv. Drug Deliv. Rev. 2009, 61 (9), 704-709.
98. Zhu L. J., Holmes B. R., Aronin N.,. CRISPRseek: A Bioconductor Package to Identify Target-Specific Guide RNAs for CRISPR-Cas9 Genome-Editing Systems. PLoS One. 2014, 9 (9), e108424.
99. Chen L., Tang L., Xiang H.,. Advances in Genome Editing Technology and Its Promising Application in Evolutionary and Ecological Studies. GigaScience. 2014, 3, 24.
100. Upadhyay S. K., Kumar J., Alok A.,. RNA-Guided Genome Editing for Target Gene Mutations in Wheat. Genes Genom. Genet. 2013, 3 (12), 2233-2238.
101. Wang Y., Cheng X., Shan Q.,. Simultaneous Editing of Three Homoeoalleles in Hexaploid Bread Wheat Confers Heritable Resistance to Powdery Mildew. Nature Biotech. 2014, 32 (9), 947-951.
102. Rathe S. K., Moriarity B. S., Stoltenberg C. B.,. Using RNA-seq and Targeted Nucleases to Identify Mechanisms of Drug Resistance in Acute Myeloid Leukemia. Sci. Rep. 2014, 4, 6048.
103. Eggert U. S., Kiger A. A., Richter C.,. Parallel Chemical Genetic and Genome-Wide RNAi Screens Identify Cytokinesis Inhibitors and Targets. PLoS Biol. 2004, 2 (12), e379.
104. Gonsalves F. C., Klein K., Carson B. B.,. An RNAi-Based Chemical Genetic Screen Identifies Three Small-Molecule Inhibitors of the Wnt/Wingless Signaling Pathway. Proc. Natl. Acad. Sci. USA. 2011, 108 (15), 5954-5963.
105. Buckingham S. D., Esmaeili B., Wood M.,. RNA Interference: From Model Organisms towards Therapy for Neural and Neuromuscular Disorders. Human Molec. Genet. 2004, 13 (Spec. No. 2), R275-R288.
106. Tsui C. C., Shankland S. J., Pierchala B. A., Glial Cell Line-Derived Neurotrophic Factor and Its Receptor RET Is a Novel Ligand-Receptor Complex Critical for Survival Response during Podocyte Injury. J. Amer. Soc. Nephrol. 2006, 17 (6), 1543-1552.